Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05043051 · ClinicalTrials.gov registry record · NA
Autoimmune Basis for Postural Tachycardia Syndrome
A NA study of Postural Tachycardia Syndrome, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05043051: Recruiting NA study of Postural Tachycardia Syndrome, sponsored by University of Oklahoma.
NCT05043051 is a NA study of Postural Tachycardia Syndrome that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 80 participants, roughly in line with the 78-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05043051, a NA study of Postural Tachycardia Syndrome, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune reaction will cause symptoms of autonomic dysfunction in some patients with postural tachycardia syndrome (POTS). The investigators further hypothesize that electrical stimulation of the vagus nerve will improve POTS symptoms, autoimmunity and inflammation.
Primary Outcome
Average of heart rate variability during the posture test
Conditions Studied
Interventions
- DEVICE Sham stimulation
- DEVICE Vagal stimulation
Study Locations (1)
Oklahoma
- Oklahoma Clinical and Translational Science Institute - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-01-14 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What NCT05043051 shows while recruiting
NCT05043051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, roughly in line with the 78-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target.
The record links to 1 condition, with Postural Tachycardia Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Sham stimulation is the first listed.
NCT05043051 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05043051 about?
NCT05043051 is a clinical study titled "Autoimmune Basis for Postural Tachycardia Syndrome". The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune reaction will cause symptoms of autonomic dysfunction in some patients with postural tachycardia syndrome (POTS). The investigators further hypothesize that electrical stimulation of the vagus nerve will improve...
What is the current status of trial NCT05043051?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2022-01-14. Estimated completion is 2026-07-31.
What conditions does trial NCT05043051 study?
This clinical trial studies the following conditions: Postural Tachycardia Syndrome.
What interventions are being tested in trial NCT05043051?
The interventions under investigation include: Sham stimulation (DEVICE), Vagal stimulation (DEVICE).
Who is sponsoring clinical trial NCT05043051?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05043051 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postural Tachycardia Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05043051's enrollment target sits among peer trials
80 6th of 19 higher than 14 of 19 other Postural Tachycardia Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postural Tachycardia Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?
RECRUITING · NA
-
Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)
ACTIVE NOT RECRUITING · NA
-
Acute Salt Handling in Orthostatic Intolerance
ACTIVE NOT RECRUITING · NA
-
fMRI in Postural Tachycardia Syndrome
ACTIVE NOT RECRUITING · NA
-
Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening
ACTIVE NOT RECRUITING · NA
-
Breathing Device in Postural Orthostatic Tachycardia Syndrome (POTS)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI